Edwards Lifesciences (EW) Stock Forecast and Price Target (2026)

Last updated November 2026

Short answer

27 analysts covering Edwards Lifesciences (EW) carry an average price target of $111.64 as of November 2026, +4.2% against the $107.11 share price on November 16, 2026. The published targets run from $84.00 to $120.00, a spread of 32% of the average, so the disagreement is moderate. The rating split is 25 buy, 4 hold, 1 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.

EW analyst price targets

Price
$107.11
Average target
$111.64
Median target
$115.00
Implied vs price
+4.2%
Target range
$84.00 to $120.00
Analysts covering
27
Ratings
25 buy4 hold1 sell

EW analyst data as of November 2026, sourced from Yahoo Finance and may be delayed. The price is the last one Yahoo Finance reported on November 16, 2026.A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.

The average target of $111.64 sits roughly in line with the $107.11 price, +4.2%. The median is $115.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

What the EW target range actually tells you

The published targets span $84.00 to $120.00. That gap is 32% of the average target, which counts as moderate disagreement. A spread like this is fairly typical: enough agreement that the average means something, enough disagreement that it should not be treated as precise.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the EW is it a buy page.

Recent analyst actions on EW

FirmActionTargetPriorDate
UBSRaised (Buy)$118.00$110.00November 6, 2026
JP MorganRaised (Overweight)$120.00$105.00November 5, 2026
CitigroupRaised (Buy)$117.00$110.00November 5, 2026
Leerink PartnersRaised (Outperform)$112.00$101.00November 5, 2026
RBC CapitalRaised (Outperform)$115.00$110.00November 5, 2026
BarclaysRaised (Overweight)$120.00$110.00November 5, 2026
BernsteinRaised (Market Perform)$106.00$99.00November 5, 2026
Piper SandlerRaised (Overweight)$115.00$101.00November 5, 2026
Truist SecuritiesRaised (Buy)$118.00$113.00November 5, 2026
Wells FargoRaised (Overweight)$113.00$100.00November 5, 2026
Evercore ISI GroupRaised (Outperform)$112.00$102.00November 5, 2026
BTIGRaised (Buy)$115.00$110.00November 5, 2026

The most recent published rating actions on EW within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.

In the last six months there have been 12 raises and 0 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.

How analysts rate EW

Of the analysts with a published rating, 25 say buy, 4 say hold, and 1 says sell, so 83% carry a buy. That buy share has risen over the last three months, so sentiment is drifting more positive.

The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

Why a EW price target is not a prediction

  • It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
  • The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
  • Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
  • Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

EW earnings and revenue forecast

For the fiscal year ending Dec 2026, the 29 analysts publishing estimates on EW expect earnings of $3.01 per share (+18% on the year before) and revenue of $6.8 billion (+12%).

PeriodEPS estimateEPS growthRevenue estimateRevenue growth
Quarter ending Dec 2026
next quarter to report, 24 analysts
$0.66
$0.64 to $0.70
+14%$1.7 billion+8.9%
Quarter ending Mar 2027
the quarter after, 19 analysts
$0.84
$0.77 to $0.90
+8.0%$1.8 billion+9.0%
Fiscal year ending Dec 2026
fiscal year next to report, 29 analysts
$3.01
$2.97 to $3.05
+18%$6.8 billion
$6.7 billion to $6.9 billion
+12%
Fiscal year ending Dec 2027
the fiscal year after, 29 analysts
$3.40
$3.31 to $3.51
+13%$7.5 billion
$7.3 billion to $7.7 billion
+9.8%

Consensus estimates for EW published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Edwards Lifesciences next reports on November 4, 2026, which is when these figures get tested against actual results.

What Edwards Lifesciences actually reported for Q3 2026, line by line against the year before, is on the EW earnings page.

Is there a 2030 forecast for EW?

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering EW do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $3.40 per share, +13% on the fiscal year ending Dec 2026 estimate of $3.01. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of November 2026, EW trades at about 59.9 times trailing earnings and 30.3 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Edwards Lifesciences can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

What could move EW from here

In short: the drivers cited most often are TAVR leadership and label expansion, TMTT as the growth engine, High margins and strong cash generation. The risk cited most often against it is edwards faces several headwinds at once.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the EW is it a buy page.

Your questions about Edwards Lifesciences

Ask Walnut's AI anything about EW and see how it fits what you own.

FAQ

What is the price target for Edwards Lifesciences (EW)?

+

The average analyst price target for EW is $111.64 as of November 2026, across 27 analysts. The average is +4.2% against the $107.11 share price on November 16, 2026, so the consensus sits roughly in line with where the stock trades. The median target, which is less distorted by one extreme view, is $115.00. Targets move constantly; verify the current figure before relying on it.

How high could EW go?

+

The highest published target is $120.00, which is +12.0% against the $107.11 price. It is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $84.00. The gap between them answers this question best: analysts who all follow Edwards Lifesciences closely disagree by 32% of the average target, so treat any single number as one scenario.

How many analysts cover EW?

+

27 analysts publish estimates on EW as of November 2026. Of those with a published rating, 25 say buy, 4 hold, and 1 sell, so 83% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.

Are analyst price targets for EW accurate?

+

Treat them as informed opinion, not measurement. Two things matter here. Sell-side ratings skew positive across the market, and EW is no exception at 83% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.

Has the EW price target been raised or cut recently?

+

In the last six months there have been 12 raises and 0 cuts among the published actions on EW. The most recent was UBS, which raised its target to $118.00 from $110.00 on November 6, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.

Is analyst sentiment on EW improving?

+

Over the last three months the share of analysts rating EW a buy has been rising. The shift is in opinion, not in the business, and it often lags the news that caused it. It is best read alongside the target revisions.

What are analysts' earnings estimates for Edwards Lifesciences (EW)?

+

For the fiscal year ending Dec 2026, the 29 analysts publishing estimates on EW expect earnings of $3.01 per share (+18% on the year before) and revenue of $6.8 billion (+12%). For the fiscal year ending Dec 2027, the consensus is $3.40 per share, +13% on the year before. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.

When does EW report earnings next?

+

Edwards Lifesciences's next earnings report is scheduled for November 4, 2026. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.

What is the EW stock price prediction for 2030?

+

There is no published one. Analyst targets run to about twelve months and no firm covering EW publishes a 2030 figure, so any site showing one has extrapolated a growth rate of its own. The answerable version of the question is what the current price already assumes about Edwards Lifesciences's earnings, which the forward multiple on this page sets out, and what would have to change for that to break.

Will EW go up in 2026?

+

Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is useful and different from a prediction. The risk most often cited against Edwards Lifesciences: Edwards faces several headwinds at once. Walnut is not an investment adviser.

Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.

Forecasts for similar stocks